<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945841</url>
  </required_header>
  <id_info>
    <org_study_id>V44_13S</org_study_id>
    <secondary_id>2009-010565-23</secondary_id>
    <nct_id>NCT00945841</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010</brief_title>
  <official_title>A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of a Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010 When Administered to Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is an annual trial for registration of inactivated split influenza vaccine with&#xD;
      strain composition for season 2009/2010.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21</measure>
    <time_frame>21 days (-1/+7)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of safety of inactivated split influenza vaccine</measure>
    <time_frame>21 days (-1/+7)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Seasonal Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>inactivated split influenza vaccine</intervention_name>
    <description>1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects eligible for enrollment into this study are male and female adults who are&#xD;
&#xD;
          1. ≥ 18 years of age, mentally competent, willing and able to give informed consent prior&#xD;
             to study entry&#xD;
&#xD;
          2. Able to comply with all study requirements&#xD;
&#xD;
          3. In good health as determined by:&#xD;
&#xD;
               -  Medical history;&#xD;
&#xD;
               -  Physical examination;&#xD;
&#xD;
               -  Clinical judgment of the investigator. Informed consent must be obtained for all&#xD;
                  the subjects before enrollment into the study after the nature of the study has&#xD;
                  been explained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are not to be enrolled into the study if at least one of the following criteria is&#xD;
        fulfilled:&#xD;
&#xD;
          1. They have any serious chronic or acute disease (in the judgment of the investigator)&#xD;
             including but not limited to:&#xD;
&#xD;
               -  Cancer, except for localized skin cancer;&#xD;
&#xD;
               -  Advanced congestive heart failure;&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease (COPD);&#xD;
&#xD;
               -  Autoimmune disease (including rheumatoid arthritis);&#xD;
&#xD;
               -  Acute or progressive hepatic disease;&#xD;
&#xD;
               -  Acute or progressive renal disease;&#xD;
&#xD;
               -  Severe neurological or psychiatric disorder;&#xD;
&#xD;
               -  Severe Asthma.&#xD;
&#xD;
          2. History of any anaphylactic reaction and/or serious allergic reaction following a&#xD;
             vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to&#xD;
             ovalbumin, chicken protein, chicken feathers, influenza viral protein neomycin or&#xD;
             polymyxin).&#xD;
&#xD;
          3. Known or suspected (or have a high risk of developing) impairment/alteration of immune&#xD;
             function (excluding that normally associated with advanced age) resulting for example&#xD;
             from:&#xD;
&#xD;
               -  Receipt of immunosuppressive therapy (any parental or oral cortical steroid or&#xD;
                  cancer chemotherapy/radiotherapy) within the past 60 days and for the full length&#xD;
                  of the study;&#xD;
&#xD;
               -  Receipt of immunostimulants;&#xD;
&#xD;
               -  Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma&#xD;
                  derivatives within the past 3 months and for the full length of the study.&#xD;
&#xD;
               -  Suspected or known HIV infection or HIV-related disease.&#xD;
&#xD;
          4. Known or suspected history of drug or alcohol abuse.&#xD;
&#xD;
          5. They have a bleeding diathesis or conditions associated with prolonged bleeding time&#xD;
             that in the investigator's opinion would interfere with the safety of the subject;&#xD;
&#xD;
          6. Women who are pregnant or woman of childbearing potential unwilling to practice&#xD;
             acceptable contraception for the duration of the study (21 days). Female who pregnant&#xD;
             of nursing (breastfeeding) mothers of females of childbearing age who do not plan to&#xD;
             use acceptable birth control measures, for the duration of the study. Adequate&#xD;
             contraception is defined as hormonal (oral, injection, transdermal patch, implant,&#xD;
             cervical ring), barrier (condom or diaphragm), intrauterine device (IUD) or monogamous&#xD;
             relationship with vasectomized partner who has been vasectomized for 6 months or more&#xD;
             prior to the subject's study entry.&#xD;
&#xD;
          7. Influenza vaccination or laboratory confirmed influenza within the last 6 months and&#xD;
             more than one influenza vaccination within the past 12 months.&#xD;
&#xD;
          8. Within the past 4 weeks they have received:&#xD;
&#xD;
               -  Another vaccine;&#xD;
&#xD;
               -  Any investigational agent.&#xD;
&#xD;
          9. Any acute or chronic infection requiring systemic antibiotic treatment or antiviral&#xD;
             therapy within the last 7 days.&#xD;
&#xD;
         10. They have experienced fever (i.e., axillary temperature ≥ 38°C) within the last 3&#xD;
             days.&#xD;
&#xD;
         11. Simultaneous participation in another clinical study.&#xD;
&#xD;
         12. Any condition, which, in the opinion of the investigator, might prevent the subject&#xD;
             from participation or interfere with the evaluation of the study objectives.&#xD;
&#xD;
         13. Severely obese with Body Mass Index (BMI) &gt; 35.&#xD;
&#xD;
         14. Site personnel involved in evaluation of safety and their immediate relatives are&#xD;
             excluded from participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Herborn</city>
        <zip>35745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis Vaccines</organization>
  </responsible_party>
  <keyword>influenza vaccine</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

